Hence, our findings imply that HER2 mRNA overexpression does not occur frequently in this subtype and supports the recommendation of the 2018 HER2 testing guidelines to classify breast cancers with HER2 IHC2+ and FISH group 2 as HER2 negative. The gene discussed is ERBB2; the disease is breast carcinoma.